Skip to content

CXCR4 Targeted PET Imaging in APA Preoperative Localization Diagnosis

A Single Center Study on the Evaluation of Diagnostic Efficacy of CXCR4 Targeted PET Imaging in Primary Aldosteronism

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05839483
Enrollment
50
Registered
2023-05-03
Start date
2023-05-30
Completion date
2024-12-31
Last updated
2023-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aldosterone-Producing Adenoma

Keywords

Hypertension, Hypokalemia, Adrenal adenoma

Brief summary

The goal of this clinical trial is to evaluate the effectiveness of CXCR4 targeted PET imaging in preoperative localization diagnosis of primary aldosteronism (PA). Participants diagnosed with PA will be asked to be scanned by 68Ga-PentixaFor PET, and then underwent adrenal venous sampling (AVS). Then, the responsible adrenal adenoma will be resected by adrenalectomy, and examined with pathological section and staining. Researchers will compare the sensitivity and specificity between 68Ga-PentixaFor PET imaging and AVS in preoperative localization diagnosis of PA.

Interventions

DIAGNOSTIC_TESTCXCR4

Participants diagnosed with PA will be asked to be scanned by 68Ga-PentixaFor PET imaging.

Sponsors

Zhongnan Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Patients with PA, confirmed by an elevated aldosterone/renin ratio (ARR) and an intravenous salt loading test. * The patient has provided written informed consent authorisation before participating in the study. * The patient is 18 to 70 years of age at the time of consent.

Exclusion criteria

* Refusal by the patients to undergo 68Ga-PentixaFor PET/CT, AVS, CT, or adrenalectomy. * Suspicion of familial hyperaldosteronism type 1 (FH-1) or type 3 (FH-3). * Suspicion of adrenocortical carcinoma. * Severe comorbidity potentially interfering with treatment or health-related quality of life. * Patients need to take drugs that interfere with clinical research. * Any medical condition present that in the opinion of the investigator will affect patients clinical status. * Pregnancy or lactation. * Estimated glomerular filtration rate \<40mL/min/1.73m2. * Interfering treatment in between 68Ga-PentixaFor PET/CT and AVS.

Design outcomes

Primary

MeasureTime frameDescription
reninimmediately after admissionmeasure the level of renin in blood
aldosteroneimmediately after admissionmeasure the level of aldosterone in blood
SUVmaximmediately after 68Ga-PentixaFor PET imagingmeasure the maximum standardized uptake value of adrenal adenoma, liver, and lateral normal adrenal
sensitivityimmediately after pathological examinationthe sensitivity of 68Ga-PentixaFor PET imaging in preoperative localization diagnosis of PA
specificityimmediately after pathological examinationthe specificity of 68Ga-PentixaFor PET imaging in preoperative localization diagnosis of PA
positive predictive value,PPVimmediately after pathological examinationthe PPV of 68Ga-PentixaFor PET imaging in preoperative localization diagnosis of PA
negative predictive value, NPVimmediately after pathological examinationthe NPV of 68Ga-PentixaFor PET imaging in preoperative localization diagnosis of PA

Countries

China

Contacts

Primary ContactZhe Meng
mengzhe@whu.edu.cn+86 15387041020

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026